Novo Nordisk Foundation

Novo Nordisk Foundation is a Danish commercial foundation and one of the world's largest philanthropic organizations, dedicated to improving health and sustainability. Established in 1924, it holds controlling interests in several major Danish companies, most notably Novo Nordisk and Novozymes, using its vast returns to fund scientific research and development. The foundation operates with a dual mandate, aiming to create both societal value through its grants and long-term financial growth through its commercial holdings. Its activities span from funding basic biomedical research at institutions like the University of Copenhagen to supporting global initiatives in areas such as climate change and infectious diseases.

History

The foundation's origins trace back to 1924 when August Krogh, a Nobel laureate, and his wife Marie Krogh obtained a license for Insulin production from Canadian researchers Frederick Banting and Charles Best. This led to the creation of Nordisk Insulinlaboratorium, a precursor to Novo Nordisk. In 1989, the separate companies Novo Industri and Nordisk Gentofte merged, and the Novo Nordisk Foundation was established as the holding entity to ensure the company's continued independence and Danish ownership. A pivotal restructuring occurred in 2000 when Novozymes was spun off as an independent company, with the foundation retaining controlling stakes in both entities. Throughout the 21st century, the foundation has dramatically expanded its philanthropic scope and financial endowment, fueled by the global success of drugs like semaglutide and liraglutide.

Organization and governance

The foundation is governed by a Board of directors and managed by an executive management team. The board, chaired by former Novo Nordisk CEO Lars Rebien Sørensen, sets the overall strategic direction and oversees the foundation's commercial and philanthropic activities. Day-to-day operations and grant administration are led by CEO Mads Krogsgaard Thomsen. Its structure includes several specialized committees, such as for research and investment, and it operates distinct grant-awarding bodies like the Novo Nordisk Foundation Committee on Research in Nursing and Midwifery. The organization maintains its headquarters in the Tuborg Havn area of Copenhagen and adheres to the Danish Foundation Act.

Activities and focus areas

The foundation's philanthropic work is organized into several strategic focus areas, primarily within health and sustainability. In health, it funds research across the spectrum from basic biology to clinical application, with major initiatives in metabolic diseases, cardiovascular health, and Antimicrobial resistance. A flagship program is the Novo Nordisk Foundation Center for Basic Metabolic Research at the University of Copenhagen. In sustainability, it supports research into green solutions, circular bioeconomy, and Climate change mitigation, often through partnerships with institutions like the Technical University of Denmark. It also awards prestigious prizes, including the Novo Nordisk Prize and the Novo Nordisk Foundation Challenge Programme grants.

Financials and funding

With an endowment exceeding 500 billion DKK, derived from its ownership stakes, the foundation is among the wealthiest of its kind globally. Its financial engine is its controlling shareholdings in Novo Nordisk and Novozymes, whose market valuations have soared. The foundation annually channels several billion DKK into grants, project support, and donations. A significant portion of its philanthropic disbursements funds research at Danish and international universities, hospitals such as Rigshospitalet, and independent research institutes. Its investment strategy is managed to ensure long-term growth, with profits continuously recycled to expand its philanthropic impact.

Associated entities

The foundation exerts controlling ownership over several major commercial and research entities. Its two largest associated companies are the global healthcare giant Novo Nordisk and the industrial enzyme producer Novozymes. Through its ownership, it also holds a majority stake in the Novo Holdings investment arm, which manages its assets and makes venture and growth investments in the life science sector. Furthermore, it has established and funds numerous research centers, including the Novo Nordisk Foundation Center for Protein Research and the Novo Nordisk Foundation Center for Biosustainability. Its philanthropic reach extends to cultural institutions like the Experimentarium science museum.